An Investigation of Effectiveness and Safety of Varenicline Tartrate in Helping People Quit Smoking

NCT00371813 ↗

Phase 3 Completed 334 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate safety and efficacy of varenicline tartrate in helping people quit smoking

Timeline

Start: 2006-09
Primary completion: —
Completion: 2007-06

Outcome

Met primary endpoint

paper The 4-week continuous abstinence end-point was achieved by 50.3% and 31.6% in the varenicline and placebo groups, respectively (P = 0.0003) PMID 19192221 ↗

Publications

Livingstone-Banks J, Fanshawe TR, Thomas KH, Theodoulou A, Hajizadeh A, Hartman L, Lindson N. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 May 5;5(5):CD006103. doi: 10.1002/14651858.CD006103.pub8.
Wang C, Xiao D, Chan KP, Pothirat C, Garza D, Davies S. Varenicline for smoking cessation: a placebo-controlled, randomized study. Respirology. 2009 Apr;14(3):384-92. doi: 10.1111/j.1440-1843.2008.01476.x. Epub 2009 Feb 20.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Varenicline	Small molecule	—	—

Indications

No indication recorded.